Clinical Trial

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study

Study acronym: TitAN
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 15, 2026 (before its estimated July 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-20.
Status change: Not Yet Recruiting → Recruiting 2026-06-11
Trial Details
NCT Number NCT07089199
Lead Sponsor Qilu Hospital of Shandong University
Conditions NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxel
Enrollment 34 participants
Start Date 2025-07-25
Primary Completion 2026-07-10 (estimated)
Study Completion 2028-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-15